CanBas Co., Ltd. (4575.T)
JPY 992.0
(0.1%)
JPY 992.0
(0.1%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 91.98 Million JPY | -40.21% |
| 2022 | 153.84 Million JPY | -71.51% |
| 2021 | 540.02 Million JPY | -37.03% |
| 2020 | 857.63 Million JPY | -16.44% |
| 2019 | 1.02 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 91.98 Million JPY | -40.21% |
| 2023 Q4 | 91.98 Million JPY | -7.2% |
| 2023 Q3 | 99.12 Million JPY | -18.17% |
| 2023 Q2 | 121.14 Million JPY | -0.61% |
| 2023 Q1 | 121.88 Million JPY | -20.78% |
| 2022 Q4 | 153.84 Million JPY | 23.63% |
| 2022 Q3 | 124.44 Million JPY | 12444500.0% |
| 2022 Q2 | 1000.00 JPY | -100.0% |
| 2022 Q1 | 383.5 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 97.167% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -45.066% |
| GNI Group Ltd. | 26.34 Billion JPY | 99.651% |
| Linical Co., Ltd. | 10.3 Billion JPY | 99.107% |
| Trans Genic Inc. | 3.81 Billion JPY | 97.587% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 84.414% |
| Soiken Holdings Inc. | 697.02 Million JPY | 86.803% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 96.955% |
| AnGes, Inc. | 2.78 Billion JPY | 96.702% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | 82.09% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.898% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | 73.961% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 94.425% |
| Carna Biosciences, Inc. | 472.35 Million JPY | 80.526% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 91.589% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 88.641% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 84.507% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 97.838% |
| PeptiDream Inc. | 29.11 Billion JPY | 99.684% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 83.762% |
| Ribomic Inc. | 155.8 Million JPY | 40.961% |
| SanBio Company Limited | 2.25 Billion JPY | 95.921% |
| Healios K.K. | 11.28 Billion JPY | 99.185% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | 63.391% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 75.071% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | 61.909% |
| StemRIM | 187 Million JPY | 50.809% |
| CellSource Co., Ltd. | 677.73 Million JPY | 86.427% |
| FunPep Company Limited | 189.32 Million JPY | 51.412% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 84.59% |
| Stella Pharma Corporation | 1.44 Billion JPY | 93.628% |
| TMS Co., Ltd. | 97.68 Million JPY | 5.836% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -0.54% |
| Cuorips Inc. | 200.96 Million JPY | 54.226% |
| K Pharma,Inc. | 209.13 Million JPY | 56.015% |
| Takara Bio Inc. | 11.42 Billion JPY | 99.195% |
| ReproCELL Incorporated | 741.03 Million JPY | 87.587% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 89.976% |
| StemCell Institute Inc. | 3.85 Billion JPY | 97.611% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 89.874% |
| CellSeed Inc. | 301.04 Million JPY | 69.444% |